Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijo Bilusic

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
Pageof 8